Version 1
: Received: 25 February 2022 / Approved: 30 March 2022 / Online: 30 March 2022 (14:49:26 CEST)
How to cite:
Chaves, P.; Garrido, M.; Oliver, J.; Pérez-Ruiz, E.; Barragán, I.; Rueda-Domínguez, A. Preclinical models in Head and Neck Squamous Cell Carcinoma. Preprints2022, 2022030391. https://doi.org/10.20944/preprints202203.0391.v1.
Chaves, P.; Garrido, M.; Oliver, J.; Pérez-Ruiz, E.; Barragán, I.; Rueda-Domínguez, A. Preclinical models in Head and Neck Squamous Cell Carcinoma. Preprints 2022, 2022030391. https://doi.org/10.20944/preprints202203.0391.v1.
Cite as:
Chaves, P.; Garrido, M.; Oliver, J.; Pérez-Ruiz, E.; Barragán, I.; Rueda-Domínguez, A. Preclinical models in Head and Neck Squamous Cell Carcinoma. Preprints2022, 2022030391. https://doi.org/10.20944/preprints202203.0391.v1.
Chaves, P.; Garrido, M.; Oliver, J.; Pérez-Ruiz, E.; Barragán, I.; Rueda-Domínguez, A. Preclinical models in Head and Neck Squamous Cell Carcinoma. Preprints 2022, 2022030391. https://doi.org/10.20944/preprints202203.0391.v1.
Abstract
Head and neck cancer is the sixth most frequent cancer type. Drug resistance and toxicity are common challenges of the existing therapies, making the development of reliable preclinical models essential for the study of the involved molecular mechanisms as well as for eventual intervention approaches that improve the clinical outcome. Preclinical models of head and neck squamous cell carcinoma have been traditionally based in cell lines and murine models. In this review, we will go over the most frequently used preclinical models, from immortalized-cell and primary tumour cultures in monolayer or 3D, to the currently available animal models. We will scrutinize their efficiency in mimicking the molecular and cellular complexity of head and neck squamous cell carcinoma. Finally, the challenges and opportunities of other envisaged putative approaches, as well as the potential of the preclinical models to further develop customized therapies will be discussed.
Keywords
HNSCC; preclinical model; cancer therapy
Subject
MEDICINE & PHARMACOLOGY, Oncology & Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
